Effect of Valacyclovir on Viral Shedding in Immunocompetent Patients With Recurrent Herpes Simplex Virus 2 Genital Herpes: A US-Based Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Fife, Kenneth H.; Warren, Terri J.; Ferrera, R. David; Young, Douglas G.; Justus, Scott E.; Heitman, Catherine K.; Burroughs, Scott M.
October 2006
Mayo Clinic Proceedings;Oct2006, Vol. 81 Issue 10, p1321
Academic Journal
OBJECTIVE: To determine the efficacy of daily suppressive therapy with a l-g dose of valacyclovir in reducing total (clinical and sub-clinical) herpes simplex virus 2 (HSV-2) shedding compared with placebo in immunocompetent patients diagnosed as having recurrent HSV-2 genital herpes. PATIENTS AND METHODS: From June 18, 2004, to December 17, 2004, patients from 27 US sites with a history of 6 or more genital herpes recurrences per year were randomized in a 3:1 ratio to receive 1 g/d of valacyclovir or placebo. During the double-blind suppressive therapy, patients were provided with the study drug (500-mg valacyclovir caplets or matching placebo) and instructed to take 2 caplets once daily without regard to meals for 60 days. Daily genital and anal or rectal swabs were self-collected during the 60-day study period for evaluation of HSV-2 viral shedding as determined by quantitative type-specific polymerase chain reaction assay. RESULTS: One hundred fifty-two patients were randomized into this study, 43 to placebo and 109 to 1 g/d of valacyclovir. A total of 134 completed the study (40 placebo [93%], 94 valacyclovir [86%]), and 18 prematurely withdrew (3 placebo [7%], 15 valacyclovir [14%]). Valacyclovir significantly reduced the percentage of days with total (clinical and subclinical) HSV-2 shedding throughout 60 days compared with placebo, in the, intent-to-treat population, a 71% reduction in total shedding (P<.001), a 58% reduction in subclinical shedding (P<.001), and a 64% reduction in clinical shedding (P=.01) were observed. Valacyclovir was not associated with any significant toxic effects compared with placebo. CONCLUSION: This study demonstrated that 1 g/d of valacyclovir administered for 60 days was generally well tolerated and was an effective suppressive therapy that significantly reduced total (clinical and subclinical) HSV-2 shedding compared with placebo in immunocompetent patients diagnosed as having recurrent HSV-2 genital herpes.


Related Articles

  • Vaccine prevents genital herpes in subgroup of women. Cole, Charles // Journal of Family Practice;Feb2003, Vol. 52 Issue 2, p94 

    The article presents a study on the herpes simplex virus (HSV) type-2 vaccine conducted on subjects that had regular sexual partners with genital herpes. HSV infection still occurs and is an epidemic in some populations despite the availability of antiviral agents and condoms. The infection is...

  • Acceptance and Outcome of Herpes Simplex Virus Type 2 Antibody Testing in Patients Attending an STD Clinic -- Recognized and Unrecognized Infections. LĂ–whagen, Gun-Britt; Berntsson, Matilda; Bonde, Ellen; Tunback, Petra; Krantz, Ingela // Acta Dermato-Venereologica;May2005, Vol. 85 Issue 3, p248 

    The majority of herpes simplex virus type 2 (HSV-2) genital infections are asymptomatic. We wanted to evaluate the acceptance of HSV-2 antibody testing among people attending an STD clinic and to estimate, after counselling, the percentage of recognized and unrecognized HSV-2 infections. First...

  • Herpes simplex virus type 2: epidemiology and management options in developing countries. Paz-Bailey, G.; Ramaswamy, M.; Hawkes, S. J.; Geretti, A. M. // Postgraduate Medical Journal;Jun2008, Vol. 84 Issue 992, p299 

    Genital herpes simplex virus type 2 (HSV2) is highly prevalent worldwide and an increasingly important cause of genital ulcer disease (GUD). Continued HSV2 transmission is facilitated by the large number of undiagnosed cases, the frequency of atypical disease and the occurrence of asymptomatic...

  • Genitourinary medicine clinic KC60 coding for first episode genital herpes: a lesson from north of the border? Challenor, R.; Theobald, N.; Pinsent, S.; Mullan, H. // International Journal of STD & AIDS;Aug2007, Vol. 18 Issue 8, p570 

    A survey of the accuracy of applying the KC60 diagnostic code for genital herpes: first attack (C10A) was undertaken by non-consultant career-grade doctors working in genitourinary (GU) medicine in England, Wales and Northern Ireland. In total, 148 forms were returned (58% response). Overall,...

  • A Risk-Benefit Evaluation of Aciclovir for the Treatment and Prophylaxis of Herpes Simplex Virus Infections. Leflore, S.; Anderson, P.L.; Fletcher, C.V. // Drug Safety;Aug2000, Vol. 23 Issue 2, p131 

    The objective of this article is to review and evaluate risks and benefits associated with the use of aciclovir in the treatment and prophylaxis of common manifestations of herpes simplex virus (HSV) infections in immunocompetent and immunocompromised patients. Information was found through a...

  • Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Sarisky, R. T.; Bacon, T. H.; Boon, R. J.; Duffy, K. E.; Esser, K. M.; Leary, J.; Locke, L. A.; Nguyen, T. T.; Quail, M. R.; Saltzman, R. // Archives of Virology;Sep2003, Vol. 148 Issue 9, p1757 

    Summary. A susceptibility testing program was established to determine the prevalence of resistance to penciclovir among herpes simplex virus isolates collected from patients participating in 11 world-wide clinical trials involving penciclovir (topical or intravenous formulations) or...

  • Acyclovir-Resistant Corneal HSV-1 Isolates from Patients with Herpetic Keratitis. Duan, Rui; de Vries, Rory D.; Osterhaus, Albert D. M. E.; Remeijer, Lies; Verjans, Georges M. G. M. // Journal of Infectious Diseases;9/1/2008, Vol. 198 Issue 5, p659 

    The prevalence and molecular characteristics of isolates from 173 immunocompetent patients with herpetic keratitis (HK) who were infected with acyclovir (ACV)-resistant(ACVR) corneal herpes simplex virus (HSV)-1 was determined. Isolates from 11 (6.4%) of the patients were ACVR, and 9 of these 11...

  • An annular erythema secondary to primary genital herpes. Mahto, Mrinalini; Mandal, Debashis; Beck, Michael H.; Wells, Stephen; Mahto, M; Mandal, D; Beck, M H; Wells, S // International Journal of STD & AIDS;Feb2000, Vol. 11 Issue 2, p123 

    The article provides information on the case regarding an annular erythema associated with genital herpes. Initial findings indicated that the viral swab from the genital ulcer which was sent for herpes simplex virus (HSV) culture and dark ground microscopy was positive for HSV-2 and dark ground...

  • Adherence in HIV Type 1 Prevention Trials. Baeten, Jared M. // Journal of Infectious Diseases;5/1/2010, Vol. 201 Issue 9, p1279 

    The article offers information on the results of the study on the prevention trials on the adherence of HIV Type 1. It mentions that herpes simplex virus type 2 (HSV-2) is the main cause of genital herpes that infects the majority of human immunodeficiency virus type 1 (HIV-1)-infected person...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics